+39 02 610346.1 - info@newron.com

Robert Holland

Robert Holland

Robert served as VP & Head, Personalised HealthCare & Biomarkers from 2005 to 2010 and as VP & Head, Neuroscience Therapeutic Area at AstraZeneca. He was also a member of the R&D Leadership Team at AstraZeneca until 2012. Previously, Robert has held positions in research and clinical development at Upjohn, Solvay, Rhone Poulenc and the Wellcome Foundation. He has extensive experience in the discovery, development and commercialisation of medicines for both neurological and psychiatric conditions and in the in-licensing and successful co-development of medicines originating from different kinds of partner companies. He has been a lecturer at The Royal London Hospital and at Merton College, Oxford in Human Physiology and Anatomy, respectively. He holds a medical as well as a doctorate degree from the University of Oxford. In addition to his position at Newron, he acts as Chief Medical Officer of Oxford Gene Technology IP Ltd., as Executive Director on the Board of Directors of Early Clinical Development Consulting Ltd. and as permanent consultant to the Wellcome Trust. Robert is member of Newron' Research and Development Committee. Robert is English.